{
    "nct_id": "NCT02260167",
    "title": "Effective Treatment of Alzheimer's and Dementia With the MIND Protocol",
    "status": "COMPLETED",
    "last_update_time": "2020-05-06",
    "description_brief": "Treating with measures that may improve metabolic functioning of neurons in an integrated protocol",
    "description_detailed": "Most organ failure results in modest drops in function until over 50% of function is lost. At a certain point, even modest drops in physiologic activity result in dramatic drops in clinical function. Though less homogeneous than in other organs, clinical experience and the literature suggests a similar process occurs in the brain. The hypothesis is that by using an integrated protocol to, essentially, \"tune up\" neuronal function, a 5-10 % improvement in metabolic functioning may translate to significant improvement in clinical functioning. This tune-up will include \"MIND\":\n\nM- Metabolism-- optimizing hormonal function I- Infections-- looking for and eliminating N- Nutritional and herbal support D- Drugs- Weaning subjects off unneeded medications",
    "phase": [
        "NA"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "Cognitive enhancer",
    "drug": [
        "MIND Protocol (Metabolism, Infections, Nutrition, Drug Elimination) \u2014 a multimodal mix of natural treatments and medications; no single drug specified"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial title and description state this is an integrated protocol intended to \"improve metabolic functioning of neurons\" and thereby produce clinical (cognitive) improvement, rather than testing a specific monoclonal antibody or a single small-molecule disease-modifying agent. \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "Act: Key trial details: \"Effective Treatment of Alzheimer's and Dementia With the MIND Protocol\" (NCT02260167) describes an intervention listed as \"a mix of natural treatments and medications\" aiming to \"tune up\" neuronal metabolic function with the hypothesis that a 5\u201310% metabolic improvement could yield measurable clinical cognitive gains. \ue200cite\ue202turn0search2\ue202turn0search3\ue201",
        "Act \u2014 web sources found: MedPath summary of the MIND protocol trial (Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol). \ue200cite\ue202turn0search0\ue201",
        "Act \u2014 additional registry entry summarizing the same trial and intervention details. \ue200cite\ue202turn0search1\ue201",
        "Reflect: Classification rationale \u2014 the intervention is not a single biologic (e.g., monoclonal antibody) nor a single small-molecule drug targeting canonical AD pathology (amyloid/tau). Its stated goal is to improve neuronal metabolic/cognitive function via multimodal metabolic and nutritional measures, which best fits the provided definition of a \"Cognitive enhancer\" (interventions improving cognitive function without a single pathology-targeted biologic or small molecule). There is some ambiguity because the protocol aims at metabolic/disease processes (a form of metabolic-targeted therapy), but because it is a mixed multimodal program rather than a defined biologic or small-molecule disease-modifying agent, \"Cognitive enhancer\" is the closest category. \ue200cite\ue202turn0search0\ue202turn0search2\ue201",
        "Notes / Ambiguity: The trial is a complex, multimodal therapeutic protocol (Metabolism, Infections, Nutrition, Drug Elimination). It is not a single investigational drug \u2014 no specific drug name or placebo arm is listed in the registry entries found. If you want a different classification (for example, treating it as a disease-targeted \"metabolic\" intervention), I can re-evaluate, but based on the four provided categories the best fit is \"Cognitive enhancer.\" \ue200cite\ue202turn0search0\ue202turn0search1\ue201"
    ],
    "agent_type": "J) Metabolism and Bioenergetics",
    "explanation_agent": [
        "Reason: The trial (\"Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol\", NCT02260167) explicitly states the intervention is an integrated protocol intended to \"tune up\" or improve metabolic functioning of neurons (optimizing hormonal function, nutrition, infection elimination, and medication management). This focus on improving neuronal/metabolic function maps directly to CADRO category J: Metabolism and Bioenergetics. \ue200cite\ue202turn0search0\ue202turn0search2\ue201.",
        "Act: Key trial details from registry/summary: intervention listed as \"a mix of natural treatments and medications\" under the MIND protocol with the stated hypothesis that a 5\u201310% improvement in metabolic functioning may translate to clinical cognitive gains. No single biologic or single small-molecule disease-modifying drug is specified, and the program is explicitly metabolic/nutrition-based. Based on those details I assign J) Metabolism and Bioenergetics. \ue200cite\ue202turn0search0\ue202turn0search1\ue201.",
        "Reflect: The classification was chosen because the primary stated mechanistic aim is to improve neuronal metabolic/bioenergetic function rather than to target amyloid, tau, inflammation, or a single receptor/pathway. The trial is multimodal (so \"multi-target\" could be considered), but CADRO's most specific match for interventions whose primary mechanism is metabolic/bioenergetic optimization is J. If you prefer to emphasize the multimodal nature over the mechanistic focus, R) Multi-target could be considered\u2014however J is the best specific fit given the protocol's stated metabolic aim. \ue200cite\ue202turn0search2\ue202turn0search0\ue201.",
        "Web-search supporting sources (registry/summaries used): 1) MedPath trial summary for \"Treatment of Alzheimer's and Dementia With the MIND Protocol\" (shows NCT02260167, intervention described, and detailed M/I/N/D elements). \ue200cite\ue202turn0search0\ue201. 2) ICHGCP/clinical-trials-registry summary of NCT02260167 (duplicate registry-style entry listing the same intervention description and hypothesis). \ue200cite\ue202turn0search2\ue201. 3) Alternate MedPath listing of the same trial. \ue200cite\ue202turn0search1\ue201."
    ]
}